

Sevion Therapeutics, Inc.  
Form 8-K  
October 14, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): October 14, 2015

Sevion Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Edgar Filing: Sevion Therapeutics, Inc. - Form 8-K

Delaware                                      001-31326                                      84-1368850  
(State or Other Jurisdiction                      (Commission File Number) (IRS Employer Identification No.)  
of Incorporation)

4045 Sorrento Valley Boulevard, San Diego, CA 92121  
(Address of Principal Executive Offices)                      (Zip Code)

(858) 909-0749  
(Registrant's telephone number,  
including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**Item 2.02. Results of Operations and Financial Condition.**

On October 14, 2015, Sevion Therapeutics, Inc., a Delaware corporation, (the “Company”), issued a press release to report the Company’s financial results for the fiscal year ended June 30, 2015. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

The information in this Item 2.02 and in any exhibits referred to herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit No. Description

99.1 Press Release of Sevion Therapeutics, Inc. dated October 14, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEVION  
THERAPEUTICS,  
INC.**

Dated: October 14, 2015 By: /s/ David Rector  
Name: David  
Rector  
Title: Chief  
Executive Officer